Abstract
Alzheimer disease (AD) is the most common form of dementia in the elderly and the number of individuals developing the disease is rapidly rising. Interventions focused on reducing beta-amyloid (Aβ), a component of senile plaques within the AD brain offer a promising approach to prevent or slow disease progression. In this review, we describe the immune system and cognitive and neurobiological features of a natural model of human brain aging, the beagle. The immune system of dogs shares many features of the human immune system, including developmental and aging characteristics. Further, dogs naturally accumulate human sequence Aβ as they age, which coincides with declines in learning and memory. A longitudinal study (∼2 years) of the response of aged beagles to vaccination with fibrillar Aβ1-42 indicated that despite significant clearance of Aβ, there were limited benefits in cognitive function. However, there was evidence for maintenance of executive function over time. These results are strikingly similar to reports of human clinical immunotherapy trials. We propose that the canine model complements existing animal models and will be helpful in developing new vaccine approaches to slowing or preventing Aβ pathology that can be translated to human clinical trials.
CNS & Neurological Disorders - Drug Targets
Title: Immunotherapy in a Natural Model of Aβ Pathogenesis: The Aging Beagle
Volume: 8 Issue: 2
Author(s): Vitaly Vasilevko and Elizabeth Head
Affiliation:
Abstract: Alzheimer disease (AD) is the most common form of dementia in the elderly and the number of individuals developing the disease is rapidly rising. Interventions focused on reducing beta-amyloid (Aβ), a component of senile plaques within the AD brain offer a promising approach to prevent or slow disease progression. In this review, we describe the immune system and cognitive and neurobiological features of a natural model of human brain aging, the beagle. The immune system of dogs shares many features of the human immune system, including developmental and aging characteristics. Further, dogs naturally accumulate human sequence Aβ as they age, which coincides with declines in learning and memory. A longitudinal study (∼2 years) of the response of aged beagles to vaccination with fibrillar Aβ1-42 indicated that despite significant clearance of Aβ, there were limited benefits in cognitive function. However, there was evidence for maintenance of executive function over time. These results are strikingly similar to reports of human clinical immunotherapy trials. We propose that the canine model complements existing animal models and will be helpful in developing new vaccine approaches to slowing or preventing Aβ pathology that can be translated to human clinical trials.
Export Options
About this article
Cite this article as:
Vasilevko Vitaly and Head Elizabeth, Immunotherapy in a Natural Model of Aβ Pathogenesis: The Aging Beagle, CNS & Neurological Disorders - Drug Targets 2009; 8 (2) . https://dx.doi.org/10.2174/187152709787847333
DOI https://dx.doi.org/10.2174/187152709787847333 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroimaging Outcomes in Studies of Cognitive Training in Mild Cognitive Impairment and Early Alzheimer’s Disease: A Systematic Review
Current Alzheimer Research Effect of Synthetic Cannabinoid HU210 on Memory Deficits and Neuropathology in Alzheimers Disease Mouse Model
Current Alzheimer Research Triggering Receptor Expressed on Myeloid Cells (TREM) Family and the Application of Its Antagonists
Recent Patents on Anti-Infective Drug Discovery Multivalent & Multifunctional Ligands to β-Amyloid
Current Pharmaceutical Design Clinical Use of Neurophysiological Biomarkers and Self-Assessment Scales to Predict and Monitor Treatment Response for Psychotic and Affective Disorders
Current Pharmaceutical Design Synthetic and Medicinal Prospective of Structurally Modified Curcumins
Current Topics in Medicinal Chemistry A Synthesis of Functional Neuroimaging in the Frontal Variant of Frontotemporal Dementia
Current Medical Imaging Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Cardiovascular Complications of Obesity
Current Respiratory Medicine Reviews Tyrosine Hydroxylase Gene: Another Piece of the Genetic Puzzle of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Mild Parkinsonian Signs in a Hospital-based Cohort of Mild Cognitive Impairment Types: A Cross-sectional Study
Current Alzheimer Research The Role of microRNAs in the Development of Type 2 Diabetes Complications
Current Pharmaceutical Design In Silico Ligand-Receptor Docking of Potentially Selective Butyrylcholinesterase Inhibitors Structurally Related to the Marine Natural Product Debromoflustramine B
Medicinal Chemistry Adamantane – A Lead Structure for Drugs in Clinical Practice
Current Medicinal Chemistry Glutamate Receptors as Therapeutic Targets for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Does Caffeine Affect Cardiovascular Responses?
Vascular Disease Prevention (Discontinued) Mitochondrial Biology and Neurological Diseases
Current Neuropharmacology Near-Infrared Spectroscopy (NIRS): A Non-Invasive In Vivo Methodology for Analysis of Brain Vascular and Metabolic Activities in Real Time in Rodents
Current Vascular Pharmacology Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia
Current HIV Research Memory Enhancing Effect of Black Pepper in the AlCl3 Induced Neurotoxicity Mouse Model is Mediated Through Its Active Component Chavicine
Current Pharmaceutical Biotechnology